Co-Diagnostics

Co-Diagnostics Equity Ratio

The Equity Ratio of Co-Diagnostics (CODX) as of Nov 20, 2026 is 83.37 %. In the previous year, Equity Ratio was 84.86 % — a change of -1.76% (lower).

Equity Ratio

83.37 %

YoY

-1.76%

Last updated:

Equity Ratio of Co-Diagnostics is 2025 83.37 % . Equity Ratio of Co-Diagnostics was 2024 84.86 % . It decreases by -1.76% lower compared to the previous year.

The Co-Diagnostics Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
-68.17 USD
Jan 1, 2019
78.42 USD
Jan 1, 2020
93.63 USD
Jan 1, 2021
84.03 USD
Jan 1, 2022
93.04 USD
Jan 1, 2023
90.24 USD
Jan 1, 2024
84.86 USD
Jan 1, 2025
83.37 USD
The Co-Diagnostics Equity Ratio history
YEAREquity RatioYoY
83.37 %-1.76%
84.86 %-5.96%
90.24 %-3.01%
93.04 %+10.72%
84.03 %-10.25%
93.63 %+19.39%
78.42 %-215.03%
-68.17 %-182.54%
82.59 %-135.74%
-231.09 %-25.29%
-309.32 %-679.80%
53.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Equity Ratio of Co-Diagnostics is 83.37 % in 2025.

Equity Ratio of Co-Diagnostics changed from 84.86 % to 83.37 %, representing a -1.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Co-Diagnostics

All Key Metrics — Co-Diagnostics